[1]
|
R. C. Straw, S. J. Withrow and B. E. Powers, “Management of Canine Appendicular Osteosarcoma,” Veterinary Clinics of North America—Small Animal Practice, Vol. 20, No. 4, 1990, pp. 1141-1161.
|
[2]
|
A. S. Hammer, F. R. Weeren and S. L. Padgett, “Prognostic Factors in Dogs with Osteosarcomas of the Flat or Irregular Bones,” Journal of the American Animal Hospital Association, Vol. 31, No. 4, 1995, pp. 321-326.
|
[3]
|
B. Wolfesberger, I. Walter, C. Hoelzl, J. G. Thalhamammer and M. Egerbacher, “Antioplasttic Effect of the Cyclooxygenase Inhibitor Meloxicam on Canine Osteosarcoma Cells,” Research in Veterinary Science, Vol. 80, No. 3, 2006, pp. 308-316.
http://dx.doi.org/10.1016/j.rvsc.2005.07.013
|
[4]
|
J. Kirpensteijn, E. P. M. Timmermans-sprang, E. V. Garderen, G. R. Rutteman, I. S. L-V. Leeuwen and J. A. Mol, “Growth Hormone 109 Gene Expression in Canine Normal Growth Plates and Spontaneous Osteosarcoma,” Molecular and Celular Endocrinology, Vol. 197, 2002, pp. 179-185.
|
[5]
|
M. N. Mullins, S. E. Lana, W. S. Dernell, G. K. Ogilvie, S. J. Withrow and E. J. Ehrhant, “Ciclooxygenase-2 Expression in Canine Appendicular Osteosarcomas,” Journal of Veterinary Internal Medicine, Vol. 18, No. 6, 2004, pp. 859-865.
http://dx.doi.org/10.1111/j.1939-1676.2004.tb02633.x
|
[6]
|
C. Khanna, J. Khan, P. Nguyen, J. Prehn, J. Caylor, C. Yeung, J. Trepel, P. Meltzer and L. Helman, “Metastasis-Associated Differences in Gene Expression in a Murine Model of Osteosarcoma,” Cancer Research, Vol. 61, No. 9, 2001, pp. 3750-3759.
|
[7]
|
W. S. Dernell, N. P. Ehrhart, R. C. Straw and D. M. Vail, “Tumor of the Skeletal System,” In: S. J. Withrow and D. M. Vail, Small Animal Clinical Oncology, 4th Edition, 2007, pp. 540-582.
|
[8]
|
R. Gorlick and C. Khanna, “Osteosarcoma,” Journal of Bone and Mineral Research, Vol. 25, No. 4, 2010, pp. 683-691. http://dx.doi.org/10.1002/jbmr.77
|
[9]
|
G. Brasileiro Filho, “Sistema ósteo-Articular,” In: “Bogliolo Patologia,” 7th Edition, Guanabara Koogan, Rio de Janeiro, 2006, pp. 979-1035.
|
[10]
|
R. I. Freshney, “Culture of Animals Cells,” 6th Edition, John Wiley & Sons, Inc., New Jersey, 2010, p. 732.
http://dx.doi.org/10.1002/9780470649367
|
[11]
|
P. Loukopoulos, T. O’brien, M. Ghoddusi, B. A. Mungall and W. F. Robinson, “Characterisation of Novel Canine Osteosarcoma Cell Lines Producing High Levels of Matrix Metalloproteinases,” Research in Veterinary Science, Vol. 77, No. 2, 2004, pp. 131-141.
http://dx.doi.org/10.1016/j.rvsc.2004.01.006
|
[12]
|
G. Finak, N. Bertos, F. Pepin, S. Sadekova, M. Souleimanova, H. Zhao, H. Chen, G. Omeroglu, S. Meterissian, A. G. Meroglu, M. Hallett and M. Park, “Stromal Gene Expression Predicts Clinical Outcome in Breast Cancer,” Nature Medicine, Vol. 14, 2008, pp. 518-527.
http://dx.doi.org/10.1038/nm1764
|
[13]
|
G. Gasparini, R. Longo, R. Sarmiento and A. Morabito, “Inhibitors of Cyclo-Oxigenase 2: A New Class of Anticancer Agents?” The Lancet Oncology, Vol. 4, No. 10, 2003, pp. 605-615.
http://dx.doi.org/10.1016/S1470-2045(03)01220-8
|
[14]
|
G. Singh-Ranger, M. Salhab and K. Mokbel, “The Role of Cyclooxygenase-2 in Breast Cancer: Review,” Breast Cancer Res. Treat, Vol. 109, No. 2, 2008, pp. 189-198.
http://dx.doi.org/10.1007/s10549-007-9641-5
|
[15]
|
C. Waskewich, R. D. Blumenthal, H. Li, R. Sein, D. M. Goldenberg and J. Burton, “Celecoxib Exhibits the Greatest Potency Amongst Cyclooxygenase (COX) Inhibitors for Growth Inhibition of COX-2-Negative Hematopoietic and Epithelial Cell Lines,” Cancer Research, Vol. 62, No. 7, 2002, pp. 2029-2033.
|
[16]
|
S. I. Mohammed, K. N. M. Khan, R. S. Sellers, M. G. Hayek, D. B. Denicola, L. Wu, P. L. Bonney and D. W. Knapp, “Expression of Cyclooxygenase-1 and 2 Naturally-Occuring Canine Cancer,” Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 70, No. 5, 2004, pp. 479-483. http://dx.doi.org/10.1016/j.plefa.2003.10.002
|
[17]
|
D. Wang and R. N. Dubois, “Prostaglandins and Cancer,” An International Journal of Gastroenterology and Hepatology, Vol. 55, No. 1, 2006, pp. 115-122.
|
[18]
|
S. Gupta, V. M. Adhami, M. Subbarayan, G. T. Maclennan, J. S. Lewin, U. O. Hafeli, P. Fu and H. Mukhtar, “Suppression of Prostate Carcinogenesis by Dietary Supplementation of Celecoxib in Transgenic Adenocarcinoma of the Mouse Prostate Model,” Cancer Research, Vol. 64, No. 9, 2004, pp. 3334-3343.
http://dx.doi.org/10.1158/0008-5472.CAN-03-2422
|
[19]
|
O. Fantappiè, M. Solazzo, N. Lasagna, F. Platini, L. Tessitore and R. Mazzanti, “P-Glycoprotein Mediates Celecoxib-Induced Apoptosis in Multiple Drug-Resistant Cell Lines,” Cancer Research, Vol. 67, No. 10, 2007, pp. 4915-4923.
http://dx.doi.org/10.1158/0008-5472.CAN-06-3952
|
[20]
|
S. Huang and F. A. Sinicrope, “Celecoxib-Induced Apoptosis Is Enhanced by ABT-737 and by Inhibition of Autophagy in Human Colorectal Cancer Cells,” Autophagy, Vol. 6, No. 2, 2010, pp. 256-269.
http://dx.doi.org/10.4161/auto.6.2.11124
|
[21]
|
S. Arico, S. Pattingre, C. Bauvy, P. Gane, A. Barbat, P. Codogno and E. Ogier-denis, “Celecoxib Induces Apoptosis by Inhibiting 3-Phosphoinositide-Dependent Protein Kinase-1 Activity in the Human Colon Cancer HT-29 Cell Line,” The Journal of Biological Chemistry, Vol. 277, No. 31, 2002, pp. 27613-27621.
http://dx.doi.org/10.1074/jbc.M201119200
|